ENDRA Life Sciences (NDRA) Depreciation & Amortization (CF) (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Depreciation & Amortization (CF) for 11 consecutive years, with $8156.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 12.83% year-over-year to $8156.0 in Q2 2026; TTM through Jun 2026 was $38551.0, a 15.53% decrease from a year earlier, with the FY2025 full-year figure at $44045.0, down 5.26% from the prior year.
• Depreciation & Amortization (CF) was $8156.0 for Q2 2026 at ENDRA Life Sciences, down from $9492.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $35265.0 in Q2 2023 and troughed at $8156.0 in Q2 2026.
• A 5-year average of $18253.8 and a median of $14543.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 81.3% in 2023 and tumbled 75.35% in 2024, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $32129.0 in 2022, then plunged by 31.88% to $21887.0 in 2023, then tumbled by 49.74% to $11000.0 in 2024, then slipped by 8.03% to $10117.0 in 2025, then slipped by 19.38% to $8156.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $8156.0 (Q2 2026), $9492.0 (Q1 2026), and $10117.0 (Q4 2025), per Business Quant data.